Concepedia

Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses

Anna Drosou, Robert S. Kirsner, Esperanza Welsh, Tory P. Sullivan, Francisco A. Kerdel

Journal of Cutaneous Medicine and Surgery · 2003 · 93 citations · 22 references

DOI

Abstract

Infliximab was well tolerated in most patients and the majority benefited from the use of infliximab.

References

22

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

Joseph Keane, Sharon K. Gershon, Robert P. Wise et al. · New England Journal of Medicine · 2001 · 3.7K citations · Full text

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld et al. · The Lancet · 1999 · 2.3K citations

, , +14

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Umesh Chaudhari, Pat Romano, LD Mulcahy et al. · The Lancet · 2001 · 903 citations

, , +10

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

P. Charles, Ruud J.T. Smeenk, Jan de Jong et al. · Arthritis & Rheumatism · 2000 · 530 citations

Infliximab for refractory sarcoidosis.

Robert P. Baughman, Elyse E. Lower · PubMed · 2001 · 214 citations